ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Sandra Van Schaeybroeck, Murugan Kalimutho, Philip D. Dunne, Robbie Carson, Wendy Allen, Puthen V. Jithesh, Keara L. Redmond, Takehiko Sasazuki, Senji Shirasawa, Jaine Blayney, Paolo Michieli, Cathy Fenning, Heinz-Josef Lenz, Mark Lawler, Daniel B. Longley, Patrick G. Johnston

Research output: Contribution to journalArticle

57 Citations (Scopus)
351 Downloads (Pure)

Abstract

There are currently no approved targeted therapies for advanced KRAS mutant (KRASMT) colorectal cancer (CRC). Using a unique systems biology approach, we identified JAK1/2-dependent activation of STAT3 as the key mediator of resistance to MEK inhibitors in KRASMT CRC in vitro and in vivo. Further analyses identified acute increases in c-MET activity following treatment with MEK inhibitors in KRASMT CRC models, which was demonstrated to promote JAK1/2-STAT3-mediated resistance. Furthermore, activation of c-MET following MEK inhibition was found to be due to inhibition of the ERK-dependent metalloprotease ADAM17, which normally inhibits c-MET signaling by promoting shedding of its endogenous antagonist, soluble "decoy" MET. Most importantly, pharmacological blockade of this resistance pathway with either c-MET or JAK1/2 inhibitors synergistically increased MEK-inhibitor-induced apoptosis and growth inhibition in vitro and in vivo in KRASMT models, providing clear rationales for the clinical assessment of these combinations in KRASMT CRC patients.
Original languageEnglish
Pages (from-to)1940-1955
Number of pages16
JournalCell Reports
Volume7
Issue number6
Early online date12 Jun 2014
DOIs
Publication statusPublished - 26 Jun 2014

Fingerprint Dive into the research topics of 'ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in <i>KRAS</i> Mutant Colorectal Cancer'. Together they form a unique fingerprint.

Cite this